Analyst Price Target is $5.21
▲ +986.16% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for LumiraDx in the last 3 months. The average price target is $5.21, with a high forecast of $14.00 and a low forecast of $0.85. The average price target represents a 986.16% upside from the last price of $0.48.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in LumiraDx.
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.